

JC37 Rec'd PCT/PTO 02 MAR 2002

FORM PTO 1390  
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

HUBR-1206 (10202655)

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

**10/088875**

INTERNATIONAL APPLICATION NO.

**PCT/EP00/09585**

INTERNATIONAL FILING DATES

**29 September 2000**

PRIORITY DATE CLAIMED

**16 September 2000 and  
October 1, 1999**

**RETARD FORM CONTAINING  $\alpha$ -LIPOIC ACID (DERIVATIVES)**


APPLICANT(S) FOR DO/EO/US **Hans SCHUHBAUER, et al.**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing 35 U.S.C. 371
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371 (f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
  - a. ☒ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☒ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

**Items 11 to 20 below concern document(s) or information included:**

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information: **PCT/ISA/210; PCT/IPEA/409**

U.S. APPLICATION NO (if known, see 37 CFR 1.49) <b>107 088875</b>		INTERNATIONAL APPLICATION NO PCT/EP00/09585		ATTORNEY'S DOCKET NUMBER HUBR-120	
17. <input checked="" type="checkbox"/> The following fees are submitted:				<b>CALCULATIONS</b> PTO USE ONLY	
<b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO And International Search Report not prepared by the EPO or JPO .....\$1040.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....\$890.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....\$740.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....\$710.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO And all claims satisfied provisions of PCT Article 33(1)-(4) .....\$100.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b> Surcharge of \$ _____ for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$ 890.00	
<b>CLAIMS</b>	<b>NUMBER FILED</b>	<b>NUMBER EXTRA</b>	<b>RATE</b>		
Total claims	-20 =	0	X		
Independent claims	1-3 =	0	X		
MULTIPLE DEPENDENT CLAIM(s) (if applicable)			X		
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 890.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above Are reduced by 1/2.					
<b>SUBTOTAL =</b>				\$ 890.00	
Processing fee of \$ _____ for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +					
<b>TOTAL NATIONAL FEE =</b>				\$ 890.00	
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). Assignment Must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31) ( _____ per property). +				\$ 40.00	
<b>TOTAL FEES ENCLOSED =</b>				\$ 930.00	
				<b>Amount to be Refunded:</b> \$	
				<b>Charged:</b> \$	
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>930.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to my Deposit Account No. <u>50-0624</u> . A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO: James R. Crawford FULBRIGHT & JAWORSKI L.L.P. 666 Fifth Avenue New York, New York 10103 (212) 318-3148 Customer No. 24972					
SIGNATURE:  NAME: James R. Crawford				39,155	

Certificate of Express Mail

This mail is being sent by Express Mail No. EL 829645035 US

In an envelope addressed to: Commissioner of Patents and Trademarks

Washington, D.C. 20231 Box PCT

On *March 20, 2002*

By: Eileen Sheffield

*Eileen Sheffield*

EL829645035US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#4/a

Applicant(s) : Schuhbauer, et al.  
Based on : PCT/EP00/09585  
International Filing  
Date : 29 September 2000  
For : RETARD FORM CONTAINING  $\alpha$ -LIPOIC ACID  
(DERIVATIVES)

March 20, 2002

Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

S I R :

Prior to examination on the merits, please amend the above-identified patent application  
as follows:

IN THE CLAIMS

Cancel claims 1-26 without prejudice and add the following new claims:

27. A sustained release form comprising
- (a) one or more cationogenic polymers,
  - (b)  $\alpha$ -lipoic acid or/and a derivative thereof and
  - (c) at least one acid different from (b).

28. A sustained release form as claimed in claim 27, wherein that component (B) comprises at least one of a racemic  $\alpha$ -lipoic acid or an enantiopure R-(+)-  $\alpha$ -lipoic acid or S- (-) -  $\alpha$ -lipoic- acid.

29. A sustained release form as claimed in claim 27, wherein that component (b) comprises a racemic dihydrolipoic acid, an enantiopure (+) - dihydrolipoic acid or (-) - dihydrolipoic acid or mixtures thereof.

30. A sustained release form as claimed in claim 27, wherein that the  $\alpha$ -lipoic acid or dihydrolipoic acid is present in whole or in part in the form of the salts thereof.

31. A sustained release form as claimed in claim 30, wherein that the salts of  $\alpha$ -lipoic acid or dihydrolipoic acid comprise cations selected from the group consisting of alkali metals and alkaline earth metals.

32. A sustained release form as claimed in claim 30, wherein that the salts of  $\alpha$ -lipoic acid or dihydrolipoic acid comprise cations from the group of iron, copper, zinc, palladium, vanadium and selenium.

33. A sustained release form as claimed in claim 30, wherein that the salts of  $\alpha$ -lipoic acid or dihydrolipoic acid comprise organic cations selected from the group consisting of open-chain or cyclic ammonium, benzylammonim, diisopropylammonium, triethylammonium, cyclohexylammonium, and complex cations, where appropriate with a metallic central atom such as, for example, iron (III), chromium (III) or cobalt (II) and neutral, cationic or anionic ligands such as, for example, water, ammonia, carbonyl, cyano or nitroso, or oxo cations such as oxovanadium(V) ( $\text{VO}_2^+$ ) or oxovanadium(IV) ( $\text{VO}_2^+$ ).

34. A sustained release form as claimed in claim 27, wherein component (a) is at least one cationogenic polymer selected from the group consisting of chitosan (poly-D-glucosamine), chitosan salts, poly-L-lysine, basic lectins and biopolymers of plant, animal or synthetic origin.

35. A sustained release form as claimed in claim 27, wherein the proportion of cationogenic polymer is from 0.1 to 90% by weight, in particular 5 to 50% by weight, in each case based on the weight of components (a), (b) and (c) in the sustained release form.

36. A sustained release form as claimed in claim 27, wherein said  $\alpha$ -lipoic acid component is present in proportions of from 0.1 to 99% by weight, in particular in proportions of from 20 to 90% by weight, in each case based on the weight of components (a), (b) and (c) in the sustained release form.

37. A sustained release form as claimed in claim 27, wherein acid component (c) comprises an organic or inorganic Brønstedt acid, in particular acetic acid selected from the group consisting of acetic acid, hydrochloric acid and glutamic acid.

38. A sustained release form as claimed in claim 27, wherein acid component (c) comprises an organic or inorganic Lewis acid, in particular carbon dioxide,  $\text{Ca}^{2+}$  or  $\text{Fe}^{2+}$ .

39. A sustained release form as claimed in claim 1, wherein that the acid component (c) comprises a complex acid, in particular hexaaquoaluminum (III)  $[\text{Al}(\text{H}_2\text{O})_6]^{3+}$  or hexacyanoiron(II) acid  $[\text{H}_4(\text{Fe}(\text{CN})_6)]$ .

40. A sustained release form as claimed in claim 27, wherein the acid component (c) comprises a polymeric acid, an isopolyacid, heptamolybdic acid ( $\text{H}_6\text{Mo}_7\text{O}_{24}$ ), or a

heteropolyacid.

41. A sustained release form as claimed in claim 27, wherein said acid component (c) is present in proportions of from 0.001 to 80% by weight based on the weight of components (a), (b) and (c) in the sustained release form.

42. A sustained release form as claimed in claim 27, further comprising at least one formulation aid, selected from the group consisting of fillers, lubricants, flow aids, mold release agents, plasticizers, blowing agents, stabilizers, colorants, extenders, binders, disintegrants, wetting agents, glidants and non-stick agents.

43. A sustained release form as claimed in claim 42, wherein that is comprises fillers inorganic fillers such as, for example, oxides of magnesium, aluminum, silicon or titanium, microcrystalline cellulose and cellulose powder, starches and derivatives thereof (for example maltodextrins), lactose, mannitol and calcium disphosphate, as lubricants stearates of aluminum and calcium, talc 9 or silicones, as flow aids magnesium stearate, colloidal silica, talc or Aerosil, as plasticizers low molecular weight polyalkylene oxides, low molecular weight organic plasticizers such as glycerol, pentaerythritol, glycerol monoacetate, diacetate or triacetate, propylene glycol, sorbitol or Na diethyl sulfonsuccinate, as colorants azo dyes, (in)organic pigments or natural coloring agents, or other conventional excipients such as sugar (alcohols), polymers, phosphates and surfactants, preferably in respective proportions between 0.02 to 50% by weight, based on the total weight.

44. A method of preparing the sustained release form of claim 42 comprising the steps of sustained release

1) Mixing component (a) with component (c), preferably in the ratio 1:2 to 1:4 by weight, then adding water to this mixture, and homogenizing the resulting mixture with the  $\alpha$ -lipoic acid component (b) in the preferred mixture: component (b) ratio of 1:0.3-0.003 by weight,

2) subjecting the homogenate from 1) to a wet granulation;

3) drying the wet granulates at temperatures between 5 and 50°C to form dry granulates; and

4) tableting the dry granules.

45. A food supplement comprising the sustained release form as claimed in claim 27.

46. A medicament comprising the sustained release form of claim 27 for producing a medicament.

47. A cosmetic comprising the sustained release form of claim 27.

48. A method of administering  $\alpha$ -lipoic acid to a subject comprising administering the sustained release form of claim 27 to a subject said administering being oral, dermal, parenteral, rectal, vaginal topical administrations.

49. The medicament of claim 46, wherein said medicament is a gel, semisolid dosage form or a solid solution.

50. A method for improving the absorption of  $\alpha$ -lipoic acid and derivatives thereof in a subject comprising preparing said sustained release form of claim 27 and administering said sustained release form to said subject, wherein controlled release of  $\alpha$ -lipoic acid or a derivative



thereof.

51. A method of providing controlled delivery of  $\alpha$ -lipoic acid or a derivative thereof in a subject comprising administering to said subject the sustained release form of claim 27 wherein said sustained release form provides controlled release of an active ingredient for a period of more than about 8 hours.

52. A method for increasing the bioavailability of  $\alpha$ -lipoic acid or/and derivatives thereof comprising preparing the sustained release form of claim 27 and administering the sustained release form to a patient.

## REMARKS

Early and favorable action on the merits is earnestly solicited.

It is not believed that any fees are due for entering this amendment. If it is determined that any fees are due, the Commissioner is authorized to charge such fees to Deposit Account No. 50-0624.

Respectfully submitted,

**FULBRIGHT & JAWORSKI L.L.P.**

By \_\_\_\_\_  
James R. Crawford  
Reg. No. 39,155

666 Fifth Avenue  
New York, N.Y. 10103  
(212) 318-3148

thereof.

51. A method of providing controlled delivery of  $\alpha$ -lipoic acid or a derivative thereof in a subject comprising administering to said subject the sustained release form of claim 27 wherein said sustained release form provides controlled release of an active ingredient for a period of more than about 8 hours.

52. A method for increasing the bioavailability of  $\alpha$ -lipoic acid or/and derivatives thereof comprising preparing the sustained release form of claim 27 and administering the sustained release form to a patient.


#### REMARKS

Early and favorable action on the merits is earnestly solicited.

It is not believed that any fees are due for entering this amendment. If it is determined that any fees are due, the Commissioner is authorized to charge such fees to Deposit Account No. 50-0624.

Respectfully submitted,

**FULBRIGHT & JAWORSKI L.L.P.**

By   
James R. Crawford  
Reg. No. 39,155

666 Fifth Avenue  
New York, N.Y. 10103  
(212) 318-3148

WO 01/24795

PCT/EP00/09585

3/p1b

Sustained release form (retarded release form)  
comprising alpha-lipoic acid (derivatives)

### Description

5

The present invention relates to a sustained release form (retarded release form) comprising  $\alpha$ -lipoic acid (derivatives) and to the use thereof.

10  $\alpha$ -Lipoic acid (thioctic acid, 1,2-dithiolane-3-pentanoic acid) occurs as a natural product in low concentrations in the form of its R enantiomer in plant and animal cells. Originally discovered as growth factor, the physiological action of  $\alpha$ -lipoic acid in  
15 hydrophilic and lipophilic media is as coenzyme in the oxidative decarboxylation of  $\alpha$ -keto carboxylic acids such as, for example, pyruvates and as antioxidants. In addition,  $\alpha$ -lipoic acid serves to regenerate vitamin C, vitamin E, glutathione and coenzyme Q10.

20

The syntheses of crude racemic  $\alpha$ -lipoic acid, of enantiopure R- or S- $\alpha$ -lipoic acid, of dihydrolipoic acid or salts thereof take place in a known or analogous manner as described or summarized, for  
25 example, in Crévisy et al., Eur. J. Org. Chem. 1998, 1949, Fadnavis et al., Tetrahedron Asym. 1998, 9, 4109, Dhar et al., J. Org. Chem. 1992, 57, 1699, Adger et al., J. Chem. Soc. Chem. Commun. 1995, 1563, Dasaradhi et al., J. Chem. Soc. Chem. Commun. 1990, 729, Gopalan  
30 et al., J. Chem. Soc. Perkin Trans. I 1990, 1897, Yadav et al., J. Sci. Ind. Res. 1990, 49, 400, Tolstikov et al., Bioorg. Khim. 1990, 16, 1670, Gopalan et al., Tetrahedron Lett. 1989, 5705.

35 The usual method for purifying crude  $\alpha$ -lipoic acid is a recrystallization from solvents (e.g. from n-pentane, cyclohexane, methylcyclohexane, ethyl acetate) or mixtures of solvents (e.g. from ethyl acetate and

hexane), as described, for example, in Brookes et al., J. Chem. Soc. Perkin Trans. I 1988, 9, Segre et al., J. Am. Chem. Soc. 1957, 3503, Walton et al., J. Am. Chem. Soc. 1955, 77, 5144, Acker et al., J. Am. Chem. Soc. 1954, 76, 6483. The crystallized  $\alpha$ -lipoic acid is then removed by filtration or centrifugation and subsequently dried by conventional methods. The crystalline  $\alpha$ -lipoic acid obtained in this way is finally processed further to the active ingredient for use.

Racemic  $\alpha$ -lipoic acid has been employed for many years for the treatment of liver disorders, paresthesias and neuropathies (e.g. autonomic and peripheral diabetic polyneuropathy); its use as efficient inhibitor of the replication of HIV-1 viruses has also been suggested (cf. Klin. Wochenschr. 1991, 69(15), 722-724). The racemate of  $\alpha$ -lipoic acid also has cytoprotective, antiinflammatory and antinociceptive (analgesic) properties. Moreover,  $\alpha$ -lipoic acid is also a radical scavenger which is readily soluble in lipophilic media. Since  $\alpha$ -lipoic acid has also been shown to stimulate glucose transport in myocytes and adipocytes (cf. Lipoic Acid in Health and Disease, Marcel Dekker Inc., New York 1997, pp. 87 et seq.) the use of this active ingredient for the treatment of disorders associated with type 2 diabetes is also possible.

Clinical studies of the pharmacokinetics of  $\alpha$ -lipoic acid have, however, shown only a very low absolute bioavailability both for the (R) enantiomer, of 24.1-38.2%, and for the (S) enantiomer, of 19.1-28.3%, of  $\alpha$ -lipoic acid. Moreover the plasma half-life after oral administration has been observed to be relatively short at less than two hours (Table 1).

Table 1 Pharmacokinetic parameters of  $\alpha$ -lipoic acid enantiomers after a single oral dose of various dosage forms (from Hermann and Niebch, Lipoic Acid in Health and Disease, Marcel Dekker, New York 1997, p. 346)

200 mg ( $\pm$ )-lipoic acid		as solution, oral		as 4x50 mg tablets		as 200 mg tablet	
Enantiomer		R	S	R	S	R	S
F <sup>(1)</sup> [s]	Mean <sup>(2)</sup>	38.2	28.3	25.9	20.9	24.1	19.1
	$\sigma$ <sup>(3)</sup>	$\pm 15.2$	$\pm 14.4$	$\pm 17.1$	$\pm 16.6$	$\pm 12.7$	$\pm 12.8$
C <sub>max</sub> [ $\mu$ g ml <sup>-1</sup> ]	Mean <sup>(2)</sup>	2.24	1.32	0.60	0.38	0.49	0.31
	$\sigma$ <sup>(3)</sup>	$\pm 1.21$	$\pm 0.69$	$\pm 0.41$	$\pm 0.28$	$\pm 0.27$	$\pm 0.16$
t <sub>max</sub> [h]	Mean <sup>(2)</sup>	0.21	0.21	0.70	0.70	0.90	0.90
	$\sigma$ <sup>(3)</sup>	$\pm 0.07$	$\pm 0.07$	$\pm 0.41$	$\pm 0.41$	$\pm 0.74$	$\pm 0.74$
t <sub>1/2</sub> [h]	Mean <sup>(2)</sup>	0.24	0.15	0.71	0.82	0.33	0.33
	$\sigma$ <sup>(3)</sup>	$\pm 0.29$	$\pm 0.08$	$\pm 0.68$	$\pm 0.99$	$\pm 0.20$	$\pm 0.24$

<sup>(1)</sup> F: bioavailability

<sup>(2)</sup> arithmetic mean

<sup>(3)</sup> standard deviation

Attempts have been made to overcome these disadvantages of unsatisfactory bioavailability and low plasma half-life with the aid of so-called sustained release forms which are intended to ensure delayed release.

5

Thus, for example, DE-A 44 13 350 discloses a solid slow release form which is in the form of pellets and which, besides a biologically active compound a) ("active substance"), comprises b) also at least one  
10 natural, semisynthetic or synthetic polymer which is insoluble in water and in gastrointestinal fluids, c) at least one water-insoluble lipophilic component with plasticizer properties for polymer b) and lubricant properties, d) at least one natural or  
15 semisynthetic hydrophilic polymer which is colloiddally soluble in water or gastrointestinal fluids, which forms highly viscous solutions or gels or at least swells ("gel former") in water or gastrointestinal fluids, and optionally one or more conventional  
20 formulation auxiliaries, the gel formers mentioned being water-insoluble chitin derivatives such as chitosan. The gel former is therefore intended in particular to make it possible for the active substance to diffuse out of the inside of the pellets. A possible  
25 active substance which is mentioned among others is thioctic acid ( $\alpha$ -lipoic acid).

This slow release form with a very complex composition is in the form of pellets which are obtained by melt  
30 extrusion at temperatures between 50 and 200°C, with preference for the so-called hot cut.

The extrusion process must be regarded as disadvantageous with this slow release form - besides  
35 its multicomponent polymer composition - especially in relation to  $\alpha$ -lipoic acid as active substance.

$\alpha$ -Lipoic acid is known to be a thermally unstable compound, which is why both the temperature of from 50 to 200°C intended for the extrusion process, and the hot cut which is likewise preferred will have adverse effects less on the polymers used but very probably on the possible active  $\alpha$ -lipoic acid, which is why serious thermal decomposition is to be assumed in the particular case of  $\alpha$ -lipoic acid.

10 The combination of a hydrophilic and amide-containing polymer with an endogenous compound in a medical composition for producing a topical barrier formulation is disclosed in WO 98/26788. A suitable polymer mentioned is, inter alia, one from the group of native  
15 chitosans or cationic derivatives thereof. The polymer must be bound to an anionic scavenger substance, inter alia in the form of the endogenous compound mentioned, which must additionally have an amino and/or thiol function. The main purpose of use of this formulation  
20 is for skin disorders with an allergic background.

A formulation for controlled release of  $\alpha$ -lipoic acid is also disclosed in WO 99/61004, according to which a therapeutic reactive amount of  $\alpha$ -lipoic acid and a  
25 binding material are combined so that the lipoic acid is protected from chemical degradation in the gastrointestinal tract and, at the same time, controlled release of the lipoic acid is ensured. The binding material used is an aqueous solution of  
30 cellulose acetate phthalate and microcrystalline cellulose. Although the examples cited in this connection show the antidiabetic effect of this formulation via the measured blood glucose level, no proof is given of the asserted sustained release action  
35 of  $\alpha$ -lipoic acid.

The object of the present invention, derived from the known prior art and, in particular, because of the

disadvantages associated therewith, is thus to develop a sustained release form which comprises  $\alpha$ -lipoic acid (derivatives), which makes it possible to improve the bioavailability of  $\alpha$ -lipoic acid and/or suitable derivatives thereof and which ensures a plasma level of  $\alpha$ -lipoic acid which remains constant for several hours in order thus to be able to improve markedly the therapeutic effect of  $\alpha$ -lipoic acid (derivatives). It was additionally intended with the novel sustained release form on the one hand to improve the absorption of  $\alpha$ -lipoic acid or suitable derivatives thereof, for example from the gastrointestinal (GI) tract, and on the other hand to ensure a controlled release of active ingredient for more than about eight hours.

This object has been achieved with a sustained release form which comprises (a) one or more cationogenic polymers, (b)  $\alpha$ -lipoic acid or/and at least one of its derivatives and (c) at least one acid different from (b), the components (a) and (b) employed favorably being physiologically and pharmacologically acceptable substances. The pH of the complete formulation is preferably 3.0 to 8.5, particularly preferably 4.0 to 7.0. It has surprisingly been found that besides a desired controlled release of active ingredient for more than eight hours and the extended GI transit time there is also faster penetration of the ingredients. However, completely unexpectedly, the sustained release form of the invention is associated with an in part drastic increase in the bioavailability of  $\alpha$ -lipoic acid and derivatives thereof.

The present invention thus represents a dosage form with which, through combination of an anionogenic active ingredient such as  $\alpha$ -lipoic acid with a special cationogenic carrier matrix, formulations which, because of predominantly ionic interactions between the



two main components, release the active ingredient with a time lag are made available.

Both racemic and enantiopure R-(+)- $\alpha$ -lipoic acid or  
5 S-(-)- $\alpha$ -lipoic acid or any mixtures thereof have proved particularly suitable for the sustained release forms of the invention. It is equally possible to employ racemic dihydrolipoic acid (6,8-dimercaptooctanoic acid) or enantiopure S-(+)-dihydrolipoic acid or R-(-)-  
10 dihydrolipoic acid or any mixtures thereof. Examples of further lipoic acid derivatives are the sulfoxides (which are also known in the literature under the name " $\beta$ -lipoic acid") 1,2-dithiolane-1-oxide-3-valeric acid and 1,2-dithiolane-2-oxide-3-valeric acid, each in  
15 enantiopure form or in the form of any mixtures or racemates of single regioisomers and/or diastereomers, or all of them. Furthermore, racemic liponamide (thioctamide) or enantiopure S-liponamide or R-liponamide or any mixtures thereof is also suitable.

20

In a further preferred embodiment of the invention, the  $\alpha$ -lipoic acid or dihydrolipoic acid is employed wholly or partly in the form of its salts as anionogenic component together with a cationogenic polymer and the  
25 acid component (c). Thus, particularly suitable salts are those comprising cations from the series of alkali metals (such as, for example, sodium or potassium) or alkaline earth metals (such as, for example, calcium or magnesium). However, it is also possible without  
30 difficulty to have recourse to other salts of  $\alpha$ -lipoic acid, in which case their cations are derived in particular from the series iron, copper, zinc, palladium, vanadium and selenium.

35 Also extremely suitable for the sustained release forms of the present invention are  $\alpha$ -lipoic acid salts which comprise organic cations and, in this case, preferably open-chain or cyclic ammonium compounds such as

benzylammonium, diisopropylammonium, triethylammonium or cyclohexylammonium, and complex cations, where appropriate with a metallic central atom such as, for example, iron(III), chromium(III) or cobalt(II) and  
5 neutral, cationic or anionic ligands such as, for example, water, ammonia, carbonyl, cyano or nitroso, or oxo cations such as oxovanadium(V) ( $\text{VO}_2^+$ ) or oxovanadium(IV) ( $\text{VO}^{2+}$ ).

10 The ionic interactions, which have already been mentioned, between the cationogenic polymer (a) and the  $\alpha$ -lipoic acid or derivatives thereof with anionogenic characteristics on the one hand, and the acid component (c) on the other hand are preferably achieved according  
15 to the invention by the use of the polymer chitosan (poly-D-glucosamine) or of a chitosan salt (such as, for example, chitosan hydrochloride, acetate or glutamate), or by use of poly-L-lysine, basic lectins (glycoproteins, e.g. from extracts such as  
20 phytohemagglutinins) or other basic polypeptides, polysaccharides (such as, for example, hexosamine sugars) or biopolymers of plant, animal or synthetic origin, and any mixtures thereof. In these cases, this mechanism of a delayed active ingredient adhesion can  
25 be described and explained on the basis of ionic, dipolar and other intermolecular interactions in principle as shown in Figure 1.

The chitosan which is preferred as cationogenic polymer  
30 can be obtained by chemical conversion (deacetylation) from chitin (poly-N-acetyl-D-glucosamine). The natural sources of chitosan include krill and the shells of shrimps, crayfish, lobsters and other representatives of the crustaceans. High molecular weight chitosan with  
35 a molecular mass of from 500 000 to 600 000 Dalton and a degree of deacetylation of 80-95% is particularly suitable for use in cosmetic formulations and in food supplements.

The use of chitosan as pharmaceutical for example as anticancer agent, for wound treatment, for arthritis and for gastrointestinal disorders, and for protecting  
5 seeds in agriculture is known.

The content of  $\alpha$ -lipoic acid component (b) in the sustained release form can be varied within wide limits. However, it has proved to be particularly  
10 advantageous to set the proportion by weight of the  $\alpha$ -lipoic acid component relative to the total weight of the sustained release form between 0.1 and 99%, in particular between 20 and 90%. The proportion by weight of cationogenic polymer should be set analogous thereto  
15 between 0.1 and 90%, and in particular between 5 and 50%.

The proportions of the acid component (c) may also vary widely: thus, proportions of from 0.001 to 80% by weight are provided according to the invention,  
20 although proportions of from 0.1 to 50% by weight and in particular proportions of from 0.1 to 25% by weight are to be preferred.

This wide range of proportions is connected not least with the large number of possible acids which are suitable according to the present invention as component (c): thus, organic or inorganic Brönsted acids such as, for example, acetic acid, hydrochloric  
30 acid and glutamic acid can be employed just as well as organic or inorganic Lewis acids, from the series of which in particular carbon dioxide,  $\text{Ca}^{2+}$  and  $\text{Fe}^{2+}$  are especially suitable.

35 However, also suitable are complex acids, in particular hexaaquoaluminum(III)  $[\text{Al}(\text{H}_2\text{O})_6^{3+}]$  or hexacyanoiron(II) acid  $[\text{H}_4(\text{Fe}(\text{CN})_6)]$ , but also polymeric acids, of which polyphosphoric acid (PPA), an isopolyacid such as, for

example, heptamolybdic acid ( $H_6Mo_7O_{24}$ ), or a heteropolyacid such as, for example, dodecatungstophosphoric acid ( $H_3[PW_{12}O_{40}]$ ) are to be particularly preferred.

- 5 Finally, it is also possible in this connection to employ any mixtures of the individual acid forms with one another but also between the individual acid forms.

10 It is also provided within the framework of the invention to employ conventional formulation aids, which are then, however, to be regarded only as additional optional component. Suitable in this connection are in particular, fillers, lubricants, flow  
15 aids, mold release agents, plasticizers, blowing agents, stabilizers, colorants, extenders, binders, disintegrants, wetting agents, glidants or non-stick agents.

From the wide range of possible suitable formulation  
20 aids, those suitable as fillers are oxides of magnesium, aluminum, silicon or titanium, microcrystalline cellulose and cellulose powder, starches and derivatives thereof (for example maltodextrins), lactose, mannitol and calcium  
25 disphosphate, as lubricants are stearates of aluminum and calcium, talc or silicones, as flow aids are magnesium stearate, colloidal silica, talc or Aerosil, as plasticizers are low molecular weight polyalkylene  
30 oxides, low molecular weight organic plasticizers such as glycerol, pentaerythritol, glycerol monoacetate, diacetate or triacetate, propylene glycol, sorbitol or Na diethyl sulfonsuccinate, as colorants are azo dyes, (in)organic pigments or natural coloring agents, or other conventional excipients such as sugar (alcohols),  
35 polymers, phosphates and surfactants, which if needed ought in each case preferably to be present in concentrations between 0.02 and 50% by weight in

relation to the total weight of the sustained release form.

Finally, besides special sustained release compositions, the present invention also provides preferred sustained release forms which are produced by a particular process:

For the sustained release form of the invention it is possible, for example, for commercially available chitosan as normally obtained from shrimp shells first to be swollen in acid aqueous solution and then to be homogenized with crystalline  $\alpha$ -lipoic acid and, after addition of the acid, wet-granulated. Tablets are then compressed by conventional methods from the dried granules. The proportion of  $\alpha$ -lipoic acid by weight in such tablets can in this case be more than 75%.

However, a procedure which is to be preferred according to the invention in this connection is one in which

- 1) component (a) is mixed with component (c), preferably in the ratio 1:2 to 1:4 by weight, then water is added to this mixture, and the resulting mixture is homogenized for example as solution with the  $\alpha$ -lipoic acid component (b) in the preferred mixture:component (b) ratio of 1:0.3-0.003 by weight,
- 2) the homogenate from 1) is subjected to a wet granulation, and the granules are dried preferably at temperatures between 5 and 50°C, particularly preferably between 25 and 40 C°, and
- 3) the dry granules are tableted.

The  $\alpha$ -lipoic acid or derivatives thereof which has/have been homogenized with chitosan or another cationogenic polymer which is suitable according to the invention and the acid component (c), and wet-granulated and tableted can, however, also be produced by any other

process. This is because in this connection it is in particular immaterial whether the  $\alpha$ -lipoic acid (derivatives) have been produced for example by recrystallization with an organic solvent or solvent mixture or whether the crude  $\alpha$ -lipoic acid is employed without any organic solvent.

Because of the favorable properties of the sustained release form of the invention, its use as food supplement is claimed just as preferably as the use as medicament and/or cosmetic, it being possible to employ the sustained release form for oral, dermal, parenteral, rectal, vaginal or local (topical) administrations.

Also provided within the framework of the present invention is the use of the claimed sustained release form as gels, semisolid dosage forms or solid solutions or else as base for producing gels, solid solutions and, in particular, semisolid dosage forms.

The following figures and examples demonstrate the advantages of the sustained release form of the invention. These show

Fig. 1 interactions between cationogenic chitosan (as example of component a)), anionogenic  $\alpha$ -lipoic acid (component b)) and another acid component (c) (depicted as anion  $A^{\ominus}$ );

Fig. 2 comparison of the effect of chitosan and acetic acid on the sustained release of  $\alpha$ -lipoic acid (the studies of  $\alpha$ -lipoic acid diffusion were carried out without chitosan, with chitosan, with chitosan 1/4 acetate, with chitosan 1/2 acetate and with chitosan 1/1 acetate. The indicated values are means ( $\pm$  SD) of at least three single experiments and

Fig. 3 the profile of release from  $\alpha$ -lipoic acid/chitosan tablets ( $\alpha$ -lipoic acid content > 75%)

5

## Examples

### 1. Diffusion study

10 In order to ensure delayed release of  $\alpha$ -lipoic acid over a period of 24 hours from the dosage form, chitosan was employed as polymeric carrier matrix for the active ingredient. Because of ionic interactions of this cationogenic polymer with the anionogenic active  
15 ingredient  $\alpha$ -lipoic acid, the latter is released continuously. In this diffusion study, the effect of chitosan on the diffusion characteristics of  $\alpha$ -lipoic acid was investigated. The results of this investigation are depicted in Fig. 2 and illustrate the  
20 strong effect of the cationogenic polymer on the diffusion characteristics of the active ingredient. Whereas the concentration equilibrium of  $\alpha$ -lipoic acid inside and outside the dialysis vessel was attainable within about 5 hours without chitosan, only 63.8%  $\pm$   
25 4.3% of this equilibrium were attained in the presence of the cationogenic polymer chitosan. On the one hand, chitosan can be hydrogenated only in ionic form in aqueous solutions and, on the other hand, preceding studies have shown unambiguously that  $\alpha$ -lipoic acid is  
30 too hydrophobic as counterion to bring about sufficient swelling of the polymer. As this diffusion study shows, addition of a rather polar acid additionally to the active ingredient is necessary in order to ensure hydration of the polymer.

35

Because of its comparatively high pKa of about 4.76, which permits ionic bonding of the active ingredient,

gives rise to no toxic risks and ensures excellent hydration of chitosan, acetic acid was chosen.

As shown by the results of the diffusion study, even  
5 low concentrations of acetic acid bring about an  
increased effect of chitosan sustaining the release of  
the active ingredient  $\alpha$ -lipoic acid: the occupation of  
every fourth amino group with chitosan with acetic acid  
(chitosan 1/4 acetate) led to a significant reduction  
10 in the rate of release of  $\alpha$ -lipoic acid from the  
polymer. One reason for this observation may be  
regarded as being an increase in free primary amino  
groups in the chitosan, which are accessible to the  
active ingredient, this being attributable to the  
15 higher degree of hydration caused by the acetic acid.

As soon as the acetic acid reaches a concentration  
which make all the primary amino groups of the polymer  
accessible to the active ingredient it is no longer  
20 possible to increase the release-sustaining effect of  
the polymer.

On the other hand, further addition of acetic acid  
appears to reduce the release-sustaining effect because  
25 the latter was significantly less at  $39.8 \pm 0.9\%$  with a  
chitosan/acetate ratio = 1:1 over a period of 5 hours  
than with a chitosan to acetate ratio = 1:2 ( $31.4 \pm$   
2.8%).

30 This observation may be explained by a competing  
behavior of the active ingredient  $\alpha$ -lipoic acid and the  
acetic acid for the freely accessible amino groups of  
the polymer. It should be noted, finally, that larger  
amounts of the active ingredient are removed from the  
35 polymer as the addition of acetic acid increases.

## 2. Release study



Investigations of the profile of release from the tablets were carried out by internationally recognized methods as are to be found, for example, in the European pharmacopoeia.

5

#### Example 1

5 g of chitosan from shrimp shells with a degree of deacetylation of more than 85% were swollen in 10 ml of glacial acetic acid and 65 ml of demineralized water at room temperature for 24 hours. This mixture was then homogenized with 24 g of  $\alpha$ -lipoic acid and wet-granulated. The granules were dried at 40°C and subsequently compressed to tablets with a diameter of 10 mm and a weight of 400 mg (Korsch, type EKO-DMS, Berlin, Germany). The content of  $\alpha$ -lipoic acid in these tablets was more than 75% (m/m).

20

#### Example 2

50 g of chitosan from shrimp shells with a degree of deacetylation of more than 85% were swollen in 100 ml of glacial acetic acid and 750 ml of demineralized water at room temperature for 24 hours. This mixture was then homogenized with 50 g of  $\alpha$ -lipoic acid and wet-granulated. The granules were dried at 40°C and subsequently compressed to tablets with a diameter of 10 mm and a weight of 400 mg (Korsch, type EKO-DMS, Berlin, Germany). The content of  $\alpha$ -lipoic acid in these tablets was about 50% (m/m).

30

#### Result of tests

Release tests with these tablets showed a strong sustaining of release through the combined use of  $\alpha$ -lipoic acid with chitosan. The dissolution profile of the  $\alpha$ -lipoic acid/chitosan tablets (400 mg) in 600 ml of demineralized water at 37°C is depicted in Fig. 3.

35

The values shown are means from three release studies with the corresponding standard deviations. This release corresponds approximately to one of 0 order during the first 8 hours. The sustaining of release shown, with which only 80% of  $\alpha$ -lipoic acid are released after 22 hours, was chosen because, on the one hand, this release in vivo is speeded up by a high electrolyte concentration and, on the other hand, part of the  $\alpha$ -lipoic acid is absorbed even in the colon.

## Claims

1. A sustained release form comprising  
(a) one or more cationogenic polymers,  
5 (b)  $\alpha$ -lipoic acid or/and a derivative thereof and  
(c) at least one acid different from (b).
2. A sustained release form as claimed in claim 1,  
10 characterized in that component (b) comprises a  
racemic  $\alpha$ -lipoic acid, an enantiopure R-(+)- or  
S-(-)- $\alpha$ -lipoic acid or mixtures thereof.
3. A sustained release form as claimed in claim 1,  
15 characterized in that component (b) comprises a  
racemic dihydrolipoic acid, an enantiopure (+)-  
dihydrolipoic acid or (-)-dihydrolipoic acid or  
mixtures thereof.
4. A sustained release form as claimed in any of  
20 claims 1 to 3, characterized in that the  $\alpha$ -lipoic  
acid or dihydrolipoic acid is present in whole or  
in part in the form of the salts thereof.
5. A sustained release form as claimed in claim 4,  
25 characterized in that the salts of  $\alpha$ -lipoic acid  
or dihydrolipoic acid comprise cations from the  
group of alkali metals or alkaline earth metals.
6. A sustained release form as claimed in claim 4,  
30 characterized in that the salts of  $\alpha$ -lipoic acid  
or dihydrolipoic acid comprise cations from the  
group of iron, copper, zinc, palladium, vanadium  
and selenium.
- 35 7. A sustained release form as claimed in claim 4,  
characterized in that the salts of  $\alpha$ -lipoic acid  
or dihydrolipoic acid comprise organic cations, in  
particular open-chain or cyclic ammonium compounds

such as benzylammonium, diisopropylammonium, triethylammonium or cyclohexylammonium, and complex cations, where appropriate with a metallic central atom such as, for example, iron(III), chromium(III) or cobalt(II) and neutral, cationic or anionic ligands such as, for example, water, ammonia, carbonyl, cyano or nitroso, or oxo cations such as oxovanadium(V) ( $\text{VO}_2^+$ ) or oxovanadium(IV) ( $\text{VO}^{2+}$ ).

10

8. A sustained release form as claimed in any of claims 1 to 7, characterized in that component (a) is a cationogenic polymer selected from chitosan (poly-D-glucosamine) or chitosan salts (such as, for example, chitosan hydrochloride, acetate, glutamate), poly-L-lysine, basic lectins (glycoproteins, e.g. from extracts such as phytohemagglutinins), or other basic polypeptides, polysaccharides (such as, for example, hexosamine sugars) or biopolymers of plant, animal or synthetic origin, and any mixtures thereof.

20

9. A sustained release form as claimed in any of claims 1 to 8, characterized in that the proportion of cationogenic polymer is from 0.1 to 90% by weight, in particular 5 to 50% by weight, in each case based on the weight of components (a), (b) and (c) in the sustained release form.

25

10. A sustained release form as claimed in any of claims 1 to 9, characterized in that the  $\alpha$ -lipoic acid component is present in proportions of from 0.1 to 99% by weight, in particular in proportions of from 20 to 90% by weight, in each case based on the weight of components (a), (b) and (c) in the sustained release form.

30

35

11. A sustained release form as claimed in any of  
claims 1 to 10, characterized in that the acid  
component (c) comprises an organic or inorganic  
Brønstedt acid, in particular acetic acid,  
5 hydrochloric acid or glutamic acid.
12. A sustained release form as claimed in any of  
claims 1 to 10, characterized in that the acid  
component (c) comprises an organic or inorganic  
10 Lewis acid, in particular carbon dioxide,  $\text{Ca}^{2+}$  or  
 $\text{Fe}^{2+}$ .
13. A sustained release form as claimed in any of  
claims 1 to 10, characterized in that the acid  
15 component (c) comprises a complex acid, in  
particular hexaaquoaluminum(III)  $[\text{Al}(\text{H}_2\text{O})_6^{3+}]$  or  
hexacyanoiron(II) acid  $[\text{H}_4(\text{Fe}(\text{CN})_6)]$ .
14. A sustained release form as claimed in any of  
20 claims 1 to 10, characterized in that the acid  
component (c) comprises a polymeric acid, in  
particular polyphosphoric acid (PPA), an  
isopolyacid such as, for example, heptamolybdic  
acid ( $\text{H}_6\text{Mo}_7\text{O}_{24}$ ), or a heteropolyacid such as, for  
25 example, dodecatungstophosphoric acid ( $\text{H}_3[\text{PW}_{12}\text{O}_{40}]$ ).
15. A sustained release form as claimed in any of  
claims 1 to 14, characterized in that the acid  
30 component (c) is present in proportions of from  
0.001 to 80% by weight, in particular in  
proportions of from 0.1 to 50% by weight and  
particularly preferably in proportions of from 1.0  
to 25% by weight, in each case based on the weight  
of components (a), (b) and (c) in the sustained  
35 release form.
16. A sustained release form as claimed in any of  
claims 1 to 15, characterized in that it

3008875-232222

additionally comprises formulation aids such as fillers, lubricants, flow aids, mold release agents, plasticizers, blowing agents, stabilizers, colorants, extenders, binders, disintegrants, wetting agents, glidants or non-stick agents.

17. A sustained release form as claimed in claim 16, characterized in that it comprises as fillers inorganic fillers such as, for example, oxides of magnesium, aluminum, silicon or titanium, microcrystalline cellulose and cellulose powder, starches and derivatives thereof (for example maltodextrins), lactose, mannitol and calcium disphosphate, as lubricants stearates of aluminum and calcium, talc or silicones, as flow aids magnesium stearate, colloidal silica, talc or Aerosil, as plasticizers low molecular weight polyalkylene oxides, low molecular weight organic plasticizers such as glycerol, pentaerythritol, glycerol monoacetate, diacetate or triacetate, propylene glycol, sorbitol or Na diethyl sulfonsuccinate, as colorants azo dyes, (in)organic pigments or natural coloring agents, or other conventional excipients such as sugar (alcohols), polymers, phosphates and surfactants, preferably in respective proportions between 0.02 to 50% by weight, based on the total weight.
18. A sustained release form as claimed in any of claims 1 to 17, characterized in that it is obtainable by
- 1) mixing component (a) with component (c), preferably in the ratio 1:2 to 1:4 by weight, then adding water to this mixture, and homogenizing the resulting mixture with the  $\alpha$ -lipoic acid component (b) in the preferred mixture:component (b) ratio of 1:0.3-0.003 by weight,

- 2) subjecting the homogenate from 1) to a wet granulation, and drying the granules at temperatures between 5 and 50°C, particularly preferably between 25 and 40°C, and
- 5 3) tableting the dry granules.
19. The use of the sustained release form as claimed in any of claims 1 to 18 for producing a food supplement.
- 10 20. The use of the sustained release form as claimed in any of claims 1 to 18 for producing a medicament.
- 15 21. The use of the sustained release form as claimed in any of claims 1 to 18 for producing a cosmetic.
22. The use as claimed in any of claims 19 to 21 for oral, dermal, parenteral, rectal, vaginal or local (topical) administrations.
- 20 23. The use as claimed in any of claims 19 to 22 as gels, semisolid dosage forms or solid solutions or as base for the production thereof.
- 25 24. The use as claimed in any of claims 19 to 23 for improving the absorption of  $\alpha$ -lipoic acid and derivatives thereof.
- 30 25. The use as claimed in any of claims 19 to 24 for prolonging the controlled delivery of active ingredient to a period of more than about 8 hours.
- 35 26. The use as claimed in any of claims 19 to 25 for increasing the bioavailability of  $\alpha$ -lipoic acid or/and derivatives thereof.

## Abstract

A sustained release form comprising  $\alpha$ -lipoic acid (derivatives) is described and is characterized in that it consists of (a) at least one cationogenic polymer, (b)  $\alpha$ -lipoic acid (derivative) and (c) at least one acid different from (b). It has surprisingly been found in this connection that, besides controlled release of active ingredient over more than 8 hours and a prolonged GI transit time, there is also faster penetration of the active ingredient. Completely unexpectedly, the sustained release form of the invention is additionally associated with an increased bioavailability of  $\alpha$ -lipoic acid and derivatives thereof.



Fig. 1




Fig. 2





Fig. 3



23316P WO

PTO/SB/01 (4-96)

Approved for use through 9/30/98 OMB 0651-0032

Type a plus sign (+) inside this box → ☒

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

# DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION

☒ Declaration Submitted with Initial Filing OR ☐ Declaration Submitted after Initial Filing

Attorney Docket Number HUBR 1206

First Named Inventor Schuhbauer, et al.

## COMPLETE IF KNOWN

Application Number

Filing Date

Group Art Unit

Examiner Name

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Sustained release form (retarded release form) comprising alpha-lipoic acid (derivatives)

(Title of the Invention)

the specification of which

☐ is attached hereto OR

☒ was filed on (MM/DD/YYYY) September 29, 2000 as United States Application Number or PCT International

Application Number PCT/EP 00/09585 and was amended on (MM/DD/YYYY) November 16, 01 (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365 (a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
199 47 330.7	German	Oct 01, 99	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
100 45 904.8	German	Sept 16, 00	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231.

(July 1996)

Please type a plus sign (+) inside this box → ☒

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**DECLARATION — Utility or Design Patent Application**

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent  
NumberParent Filing Date  
(MM/DD/YYYY)Parent Patent Number  
(if applicable)☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

24972

OR

☐ Registered practitioner(s) name/registration number listed belowPlace Customer  
Number Bar Code  
Label here

Name

Registration  
Number

Name

Registration  
Number☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to:

☐ Customer Number  
or Bar Code Label

24972

OR ☐ Correspondence address below

Name

Fulbright &amp; Jaworski L.L.P.

Address

666 Fifth Avenue

Address

New York, N.Y. 10103

City

New York

State

NY

ZIP

10103

Country

USA

Telephone

001-212-3183000

Fax

001 -212-7525958

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))

Family Name or Surname

Hans

Schubbauer

Inventor's  
SignatureX *[Signature]*

Date

X 14/02/02

Residence: City

Trostberg

State

DEX

Country

Germany

Citizenship

.DE

Post Office Address

Herzog-Otto-Strasse 18, 83308 Trostberg, Germany

Post Office Address

City

State

ZIP

Country

☒ Additional inventors are being named on the \_\_\_\_\_ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

Type a plus sign (+) inside this box → ☒

## DECLARATION

ADDITIONAL INVENTOR(S)  
Supplemental Sheet

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	Ivo	Middle Initial		Family Name	Pischel	Suffix	
Inventor's Signature	X <i>I. Pischel</i>				Date	X 27/02/2002	
Residence: City	Trostberg	State	DE	Country	Germany	Citizenship	DE
Post Office Address	Sonnenleite 6a, 83308 Trostberg, Germany						
Post Office Address							
City		State		Zip		Country	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	Andreas	Middle Initial		Family Name	Bernkop-Schnürch	Suffix	
Inventor's Signature	X <i>A. Bernkop-Schnürch</i>				Date	X 19/02/2002	
Residence: City	Wien	State	ATX	Country	Austria	Citizenship	AT
Post Office Address	Althanstrasse 14, 1090 Wien, Austria						
Post Office Address							
City		State		Zip		Country	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name		Middle Initial		Family Name		Suffix	
Inventor's Signature					Date		
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name		Middle Initial		Family Name		Suffix	
Inventor's Signature					Date		
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	

☐ Additional inventors are being named on supplemental sheet(s) attached hereto

RECEIVED FEB 27 2002

2-00

3-00